Press Releases WoodmenLife Receives Forbes 2026 America’s Best Insurance Companies Ranking As Voted By Real Policyholders January 13, 2026
Press Releases Psympl Releases Executive Whitepaper on the $124 Trillion Great Wealth Transfer, Calling Psychographics the Missing Link to Protecting and Growing AUM January 13, 2026
Press Releases Crypto Allocations by Financial Advisors Hit All-Time High in 2025: Bitwise/VettaFi Survey January 13, 2026
Press Releases Scams Involving the 2026 Prescription Drug Cap: “The Medicare Fraud of the Month for January” January 13, 2026
Press Releases 121G Consulting Unveils Financial Advantages of Domestic R&D Investment January 13, 2026
Press Releases Evention Appoints Justin Hartanov as Chief Executive Officer to Accelerate Growth, Platform Offerings and Customer Impact January 13, 2026
Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2 months ago